Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately ...

Hims & Hers Health(NYSE ... including treating sensitive areas such as erectile dysfunction and hair loss. And by expanding its offerings, it has reached a broader group of customers.

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Former US Army Sgt. Mark Millich’s sex drive plummeted — and his genitals shrank and changed shape after taking popular hair-loss drug finasteride.

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

Telehealth companies like Hims & Hers (HIMS) are aggressively marketing hair-loss medications to young men, with some patients saying they ...

Founded in 2017, Hims is a telemedicine platform that offers medical services and treatments related to sexual health, hair loss, anxiety, skin care, and more. Hims connects its customers with ...

But following its start in 2017, Hims & Hers ballooned in size to become a much-watched telehealth player; in 2021, it snagged hair-focused Honest Health and, for more than $130 million ...

Last week, the news on Hims & Hers was all about how a Texas court ruling confirmed the FDA can declare an end to the shortage of tirzepatide-based GLP-1 weight-loss drugs from Eli Lilly (NYSE ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...